Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3412548 | 0.84 | HTR2A (0.41) | HTR2ASLC6A4KCNH2L3MBTL1FFAR1 | |
| SCHEMBL13806110 | 0.82 | TAAR1 (0.41) | HTR2ASLC6A4KCNH2L3MBTL1FFAR1 | |
| SCHEMBL16752294 | 0.81 | KMT2A (0.48) | HTR2ASLC6A4KCNH2L3MBTL1FFAR1 | |
| SCHEMBL8230054 | 0.81 | GRIN2D (0.41) | L3MBTL1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13979885 | 0.80 | SLC5A2 (0.48) | HTR2ASLC6A4KCNH2FFAR1FFAR4 | |
| SCHEMBL598593 | 0.79 | TAAR1 (0.44) | L3MBTL1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6111929 | 0.79 | PNMT (0.48) | HTR2ASLC6A4KCNH2L3MBTL1FFAR1 | |
| SCHEMBL2735698 | 0.79 | HTR2A (0.41) | HTR2ASLC6A4KCNH2L3MBTL1FFAR1 | |
| SCHEMBL16998686 | 0.79 | HTR2A (0.41) | HTR2ASLC6A4KCNH2L3MBTL1FFAR1 | |
| SCHEMBL30707192 | 0.79 | HTR2A (0.41) | HTR2ASLC6A4KCNH2L3MBTL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4140695-A | Process for producing copper phthalocyanines | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1979-02-20 | — | — | US | claimed |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210145844-A1 | COMBINATION THERAPY FOR NICOTINE ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| EP-2970156-B1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
| US-7279484-B2 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | AJINOMOTO CO., INC. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-7279484-B2 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | AJINOMOTO CO., INC. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-4538003-A | TREATMENT WITH MAGNESIUM OR ZINC ORGANOMETALLIC REAGENTS IN PRESENE OF A NICKEL BIDENTATE OR TRIDENTATE PHOSPHOROUS LIGAND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| US-4140695-A | Process for producing copper phthalocyanines | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | CDK1, CDKN1A, CDKL1 | HTR2A 4528/4885SLC6A4 4870/4885KCNH2 3960/4885 |
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | HTR2A 1609/4885SLC6A4 513/4885KCNH2 2163/4885 |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | HTR2A 4216/4885SLC6A4 2477/4885KCNH2 4083/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | HTR2A 1235/4885SLC6A4 375/4885KCNH2 1884/4885 |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, CKS2 | HTR2A 4619/4885SLC6A4 4544/4885KCNH2 3800/4885 |
| US-20210145844-A1 | COMBINATION THERAPY FOR NICOTINE ADDICTION | CHRNA2, ALDH2, ALDH1A1 | HTR2A 373/4885SLC6A4 361/4885KCNH2 1314/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | HTR2A 690/4885SLC6A4 2399/4885KCNH2 1654/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | HTR2A 690/4885SLC6A4 2399/4885KCNH2 1654/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | HTR2A 1235/4885SLC6A4 375/4885KCNH2 1884/4885 |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | HTR2A 1275/4885SLC6A4 1906/4885KCNH2 1482/4885 |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | ALDH1A1, ALDH2, ALDH3A1 | HTR2A 231/4885SLC6A4 253/4885KCNH2 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.